Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29599675 | 1.00 | ALDH1A1 (0.48) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL30099834 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL219949 | 0.81 | PKM (0.33) | GOT1 | |
| SCHEMBL8194 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| Hydrochloric Acid SCHEMBL3439030 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| Water SCHEMBL28824188 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| Hydrochloric Acid SCHEMBL3710107 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL29095245 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| Hydrochloric Acid SCHEMBL3704751 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL29592061 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1743 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3494396-B1 | CHEMILUMINESCENT AND FLUORESCENT SUBSTRATE PADS AND USES THEREOF | PIERCE BIOTECHNOLOGY INC (US) | 2025-06-11 | — | — | EP | claimed |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | claimed |
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-07-25 | — | — | US | claimed |
| EP-4385988-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-06-19 | — | — | EP | claimed |
| CN-117279663-A | Antibody drug conjugate comprising antibody against human CLDN18.2 and use thereof | 乐高化学生物科学股份有限公司 | 2023-12-22 | — | — | CN | claimed |
| EP-4242202-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-09-13 | — | — | EP | claimed |
| CN-116217558-A | GLP-1 receptor agonist, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-06-06 | — | — | CN | claimed |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | claimed |
| US-20230128972-A1 | Anat Inhibitors and Methods of Use Thereof | Atomwise Inc. | 2023-04-27 | — | — | US | claimed |
| WO-2001055446-A1 | NOVEL STABILIZED FORMULATIONS FOR CHEMILUMINESCENT ASSAYS | GIRI BRIJ PAL (US) | 2001-08-02 | — | — | WO | claimed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000065349-A2 | METHOD FOR DETERMINING PLASMINOGEN ACTIVATOR INHIBITOR | CARDIOGENICS INC. (CA) | 2000-11-02 | — | — | WO | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| US-5952167-A | A REDUCIBLE SILVER SOURCE, A PHOTOCATALYST, A REDUCING AGENT, A BINDER AND A DIHALOMETHYL-SUBSTITUTED HETEROCYCLIC RING CONTAINING TWO TO FOUR NITROGEN ATOMS; ANTIFOGGING AGENTS; STORAGE STABILITY; IMAGE TONE; PHOTOSENSITIVITY | FUJI PHOTO FILM CO., LTD. (JP) | 1999-09-14 | — | — | US | claimed |
| US-5420275-A | Chemiluminescent assay, tumors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-30 | — | — | US | claimed |
| EP-0491477-A1 | Pyridopyridazine compounds and their use | Takeda Chemical Industries, Ltd. (JP) | 1992-06-24 | — | — | EP | claimed |
| US-5059605-A | Methyl 2-(pyridyloxypyrimidinyleneoxyphenylene)-3-methoxypropenoates | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128972-A1 | Anat Inhibitors and Methods of Use Thereof | AANAT, CHAT, NAT1 | ALDH1A1 616/4885MAPT 209/4885KDM4E 2931/4885 |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | ALDH1A1 4076/4885MAPT 2511/4885KDM4E 4371/4885 |
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GLP1R, GIPR, GCGR | ALDH1A1 1985/4885MAPT 468/4885KDM4E 3725/4885 |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GABRA5, SLC6A11, GABRA1 | ALDH1A1 607/4885MAPT 2714/4885KDM4E 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.